Xilio Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Xilio Therapeutics, Inc. (XLO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- Xilio Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.60M, a 18.28% increase year-over-year.
- Xilio Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.21M, a 44.04% increase year-over-year.
- Xilio Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $2.93M, a 93.27% increase year-over-year.
- Xilio Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.12M, a 28.65% decline year-over-year.
- Xilio Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $6.94M, a 7.85% increase from fiscal 2024.
- Xilio Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $6.43M, a 12.84% decline from fiscal 2023.
- Xilio Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $7.38M, a 12.37% decline from fiscal 2022.
- Xilio Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $8.42M, a 69.91% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.60M 10-Q · filed 2026-08-12 | $3.81M 10-Q · filed 2026-08-12 | $6.74M derived: sum of 3 quarters · filed 2026-08-12 | $7.86M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.21M 10-Q · filed 2026-05-12 | $5.14M derived: sum of 2 quarters · filed 2026-05-12 | $6.26M derived: sum of 3 quarters · filed 2026-05-12 | $7.62M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $2.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $4.05M derived: sum of 2 quarters · filed 2026-03-23 | $5.40M derived: sum of 3 quarters · filed 2026-08-12 | $6.94M 10-K · filed 2026-03-23 |
| 2025-09-30 | $1.12M 10-Q · filed 2025-11-13 | $2.47M derived: sum of 2 quarters · filed 2026-08-12 | $4.01M 10-Q · filed 2025-11-13 | $5.53M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $1.35M 10-Q · filed 2026-08-12 | $2.89M 10-Q · filed 2026-08-12 | $4.40M derived: sum of 3 quarters · filed 2026-08-12 | $5.98M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $1.53M 10-Q · filed 2026-05-12 | $3.05M derived: sum of 2 quarters · filed 2026-05-12 | $4.63M derived: sum of 3 quarters · filed 2026-05-12 | $6.14M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $3.09M derived: sum of 2 quarters · filed 2026-03-23 | $4.60M derived: sum of 3 quarters · filed 2026-03-23 | $6.43M 10-K · filed 2026-03-23 |
| 2024-09-30 | $1.57M 10-Q · filed 2025-11-13 | $3.08M derived: sum of 2 quarters · filed 2025-11-13 | $4.92M 10-Q · filed 2025-11-13 | $6.85M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.51M 10-Q · filed 2025-08-14 | $3.34M 10-Q · filed 2025-08-14 | $5.27M derived: sum of 3 quarters · filed 2025-08-14 | $7.13M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.83M 10-Q · filed 2025-05-08 | $3.76M derived: sum of 2 quarters · filed 2025-05-08 | $5.62M derived: sum of 3 quarters · filed 2025-05-08 | $7.42M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $3.79M derived: sum of 2 quarters · filed 2025-03-11 | $5.59M derived: sum of 3 quarters · filed 2025-03-11 | $7.38M 10-K · filed 2025-03-11 |
| 2023-09-30 | $1.86M 10-Q · filed 2024-11-07 | $3.66M derived: sum of 2 quarters · filed 2024-11-07 | $5.45M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $1.80M 10-Q · filed 2024-08-08 | $3.59M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $1.79M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $8.42M 10-K · filed 2024-04-01 | |||
| 2022-09-30 | $1.87M 10-Q · filed 2023-11-09 | $4.58M derived: sum of 2 quarters · filed 2023-11-09 | $6.61M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $2.71M 10-Q · filed 2023-11-09 | $4.74M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $2.03M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $4.96M 10-K · filed 2023-03-02 | |||
| 2021-09-30 | $1.09M 10-Q · filed 2022-11-09 | $2.09M derived: sum of 2 quarters · filed 2022-11-09 | $2.89M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $1.00M 10-Q · filed 2022-11-09 | $1.80M derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $794.00K 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $1.30M 10-K · filed 2022-03-01 | |||
| 2020-09-30 | $683.00K 10-Q · filed 2021-12-02 | $834.00K derived: sum of 2 quarters · filed 2021-12-02 | $930.00K derived: sum of 3 quarters · filed 2021-12-02 | |
| 2020-06-30 | $151.00K 10-Q · filed 2021-12-02 | $247.00K derived: sum of 2 quarters · filed 2021-12-02 | ||
| 2020-03-31 | $96.00K 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |